WHO
REGULATORY UPDATE
Update on Nitrosamine Impurities
Published: 11/10/2026Detected: 11/9/2026
Summary preview
Recognizes the ICH M7 (R2) less-than-lifetime (LTL) approach as applicable to nitrosamine impurities for products with short treatment durations, enabling adjusted acceptable intake (AI) limits.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountgastroenterology
pediatrics
infectious_disease
manufacturing
quality
clinical
safety
labeling
#nitrosamine impurities
#less-than-lifetime (LTL)
#acceptable intake (AI)
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- Invitation to a Webinar on managing reportable changes11/10/2026
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices11/10/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available11/10/2026
- VCP Updates - October 202611/10/2026
- In Vitro Diagnostics Assessment Sessions for 202711/10/2026